JG
MRNA icon

Jefferies Group’s Moderna MRNA Stock Holding History

Jefferies Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,752
Closed -$536K – 1826
2022
Q2 		$536K Sell
3,752
-31,848
-89% -$4.55M ﹤0.01% 965
2022
Q1 		$6.13M Sell
35,600
-25,800
-42% -$4.34M 0.04% 365
2021
Q4 		$15.6M Sell
61,400
-29,467
-32% -$8.62M 0.09% 182
2021
Q3 		$35M Buy
90,867
+44,104
+94% +$16.3M 0.25% 59
2021
Q2 		$11M Buy
46,763
+9,999
+27% +$1.79M 0.07% 253
2021
Q1 		$4.81M Buy
36,764
+3,764
+11% +$545K 0.04% 396
2020
Q4 		$3.45M Buy
33,000
+26,606
+416% +$2.69M 0.03% 534
2020
Q3 		$452K Buy
+6,394
New +$446K 0.01% 1008
2019
Q4 		– Sell
-81,034
Closed -$1.29M – 2825
2019
Q3 		$1.29M Buy
81,034
+17,444
+27% +$258K 0.01% 1353
2019
Q2 		$931K Buy
+63,590
New +$1.37M 0.01% 1342

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jefferies Group's MRNA Position: Q3 2022 in Review

Jefferies Group sold out of Moderna (MRNA) in Q3 2022, closing a stake of 3,752 shares — an estimated $536K sold.

Jefferies Group first reported a position in MRNA in Q2 2019 and held it in 10 quarters. The position peaked at $35M in Q3 2021. 915 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Jefferies Group reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 3,752 Moderna shares in Q3 2022, an estimated $536K.
  • Jefferies Group first reported a position in Moderna in Q2 2019 and held it in 10 quarters.
  • Jefferies Group's Moderna position peaked at $35M in Q3 2021.
  • 915 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.